AI assistant
TruScreen Group Limited — Audit Report / Information 2020
Feb 16, 2020
66285_rns_2020-02-17_7d133617-c48b-4d36-960b-a6b86d6fe473.pdf
Audit Report / Information
Open in viewerOpens in your device viewer
==> picture [261 x 38] intentionally omitted <==
NZX Announcement
17 February 2020
Appointment of Auditors
TruScreen Limited ( NZX:TRU ) (TruScreen or the Company) advises that BDO Auckland have resigned as auditors of the Company.
The Company has appointed RSM Hayes Audit Auckland as auditors of the Company with immediate effect.
The Board of Directors takes this opportunity to thank BDO Auckland for their service to the Company since listing in 2014.
- ENDS -
For more information, visit www.truscreen.com or contact:
TruScreen Investors Tony Ho Investor Relations Chairman Phone: +61 2 9237 2801 [email protected] [email protected]
About TruScreen:
TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen’s real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.
==> picture [186 x 83] intentionally omitted <==
==> picture [173 x 58] intentionally omitted <==
TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen’s target market is lowand middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen’s cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDAapproved for sale in China. The global market potential for TruScreen is significant.
For more information, visit our website at www.truscreen.com Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen- ultra-
==> picture [261 x 38] intentionally omitted <==
video/